Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 3, 2003 - Issue 1
Submit an article Journal homepage
9
Views
0
CrossRef citations to date
0
Altmetric
Review

Cost-effectiveness of nonemergency use of phenytoin

Stephanie N Davis Center for Drug Policy and Clinical Economics, University of Wisconsin Hospital and Clinics, 600 Highland Ave., Madison, WI 53792, USA. [email protected]
&
D Michael Collin Department of Pharmacy, University of Wisconsin Hospital and Clinics, 600 Highland Ave., Madison, WI 53792, USA. [email protected]
Pages 41-46 | Published online: 09 Jan 2014

References

  • Meek P, Davis SN, Collin M eta]. Guidelines for nonemergency use of parenteral phenytoin products. Arch. Intern. Med. 159, 2639–2644 (1999).
  • ••Good review of the formularyconsiderations for parental phenytoin products and recommendations for use.
  • Collin D, Gidal BE, Garnett W Reinfeldt G, Tusch G. Potential under reporting of IV phenytoin adverse events. Ann. Pharmacother. 33, 111–112 (1999).
  • Earnest MP, Mazrx JA, Drury LR. Complications of IV phenytoin for acute treatment of seizures. Recommendations for usage. JA/V/A 249, 762–765 (1983).
  • Kilarski DJ, Buchanan C, VonBehren L. Soft-tissue damage associated with iv. phenytoin. N. Eng/. J. Med 311, 1186–1187 (1984).
  • Spengler RF, Arrowsmith JB, Kilarski DJ, Buchanan C, VonBehren L, Graham DR Severe soft-tissue injury following IV infusion of phenytoin. Patient and drug administration risk factors. Arch. Intern. Med. 148,1329–1333 (1988).
  • O'Brien TJ, Meara FM, Matthews H, Vajda FJ. Prospective study of local cutaneous reactions in patients receiving IV phenytoin. Neurology57, 1508–1510 (2001).
  • •Provides insight into the incidence of phenytoin-induced adverse events.
  • Hanna DR. Purple glove syndrome: a complication of IV phenytoin. j Neurosci. NUM: 24, 340–345 (1992).
  • Bumeo JG, Andandan JV, Barley GL. A prospective study of the incidence of the purple glove syndrome. 43ilepsia 42(9), 1156–1159 (2001).
  • •Provides insight into the incidence of phenytoin-induced adverse events.
  • O'Brien TJ, Cascino GD, Therefore, EL, Hanna DR. Incidence and clinical consequences of the purple-glove syndrome in patients receiving IV phenytoin. Neurology51,1034–1039 (1998).
  • •Provides insight into the incidence of phenytoin-induced adverse events.
  • Burneo JG, Barkley GL. Prospective study of local cutaneous reactions in patients receiving IV phenytoin. Neurology58, 1134 (2002).
  • •Provides insight into the incidence of phenytoin-induced adverse events.
  • Holliday SM, Benfield P, Plosker G. Fosphenytoin. Economic implications of therapy. PharmacoEconomics 14(6), 685–690 (1998).
  • Binder L, Trujuillo J, Parker D, Cuetter A. Association of IV phenytoin toxicity with demographic clinical and dosing parameters. Am.j Emerg. Med 14, 398–401 (1996).
  • Yoon Y, Jagoda A. New anti-epileptic drugs and preparations. Pharmacol Adv Emer. Med 18(4), 755–765 (2000).
  • Cerebyx: Physicians' Desk Reference. Medical Economics Company Inc., NJ, USA, 2619–2622 (2002).
  • Pryor FM, Gidal B, Ramsay RE, DeToledo J, Morgan RO. Fosphenytoin: Pharmacokinetics and tolerance of IM loading doses. 43ilepsia 42(2), 245–250 (2001).
  • DeToledo JC, Ramsy RE. Fosphenytoin and phenytoin in patients with status epilepticus. Improved tolerability versus increased costs. Drug Safety22 (6), 459–466 (2000).
  • Jamerson BD, Dukes GE, Brower KLR, Donn KH, Messenheimer JA, Powell JR Venous irritation related to IV administration of phenytoin versus fosphenytoin. Phannacothempy14, 47–52 (1994) .
  • Johnson J, Wrenn K. Inappropriatefosphenytoin use in the ED. Aus. j Emer. Manag. 19(4), 293–294 (2001).
  • Anonymous. 2002 Drug Topics Red Book. Medical Economics Company Inc., NJ, USA (2002).
  • Armstrong EP, Sauer KA, Downey MJ. Phenytoin and fosphenytoin: a model of cost and clinical outcomes. PharmacoEconomics 19(7), 844–853 (1999).
  • •Review identifies pharrnacoeconomic considerations with regards to parental phenytoin administration.
  • Marchetti A, Magar R, Fischer J, Sloan E, Fischer P A pharmacoeconomic evaluation of iv. fosphenytoin (Cerebyx) versus iv. phenytoin (Dilantin) in hospital emergency departments. Clin. Ther. 18(5), 953–966 (1996).
  • •Review identifies pharrnacoeconomic considerations with regards to parental phenytoin administration.
  • Touchette DR, Rhoney DH. Cost-minimization analysis of phenytoin and fosphenytoin in the emergency department. Pharmacotherapy20(8), 908–916 (2000).
  • •Review identifies pharrnacoeconomic considerations with regards to parental phenytoin administration.
  • Graves N. Pharmacoeconomic considerations in treatment options for acute seizures. J. Child Neurol 13,527—S29 (1998).
  • Johnson NE, Doyle JJ. A stepwise approach to performing a preliminary pharmacoeconomic analysis: focus on fosphenytoin. P&T611-628 (1996).
  • •Review identifies pharrnacoeconomic considerations with regards to parental phenytoin administration.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.